Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer

7 Jun 2022

Abstract excerpt

BackgroundImmune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC). To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study.MethodsEligible patients had platinum-resistant OC, normal organ function, measurable disease, and received up to 5 prior regimens. The treatment included guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35671108
DOI: 10.1172/jci158800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancerPMID 35671108Read ↗

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trialSemantic proximity Read ↗

Blood Based Biomarkers of DNA Methylation Associated with Platinum Resistance in High Grade Serous Ovarian CancerSemantic proximity Read ↗

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.Semantic proximity Read ↗

Dendritic Cells Immunotherapy of Ovarian Cancer: Overview of Our AchievementsSemantic proximity Read ↗

Tumor B cell infiltration in platinum-treated advanced urothelial carcinomaSemantic proximity Read ↗

Combinatorial delivery of low-dose irradiation and immunotherapy to patients with immune-excluded tumors effectively enhances CD8<sup>+</sup>T cell functionalitySemantic proximity Read ↗

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapySemantic proximity Read ↗

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cellsSemantic proximity Read ↗

Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor TherapySemantic proximity Read ↗

Cell Cycle Activity Correlates with Increased Anti-Tumor Immunity in Diverse CancersSemantic proximity Read ↗

Decitabine reactivated pathways in platinum resistant ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.